Considering Multicriteria Decision Analysis (MCDA) Simple Scoring as an Evidence-Based HTA Methodology for Evaluating Off-Patent Pharmaceuticals (OPPs) in Emerging Markets

Diana Brixner, Nikos Maniadakis, Z. Kaló, Shanlian Hu, Jie Shen, Kalman Wijaya

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Off-patent pharmaceuticals (OPPs) represent more than 60% of the pharmaceutical market in many emerging countries, where they are frequently evaluated primarily on cost rather than with health technology assessment. OPPs are assumed to be identical to the originators. Branded and unbranded generic versions can, however, vary from the originator in active pharmaceutical ingredients, dosage, consistency formulation, excipients, manufacturing processes, and distribution, for example. These variables can alter the efficacy and safety of the product, negatively impacting both the anticipated cost savings and the population's health. In addition, many health care systems lack the resources or expertise to evaluate such products, and current assessment methods can be complex and difficult to adapt to a health system's needs. Multicriteria decision analysis (MCDA) simple scoring is an evidence-based health technology assessment methodology for evaluating OPPs, especially in emerging countries in which resources are limited but decision makers still must balance affordability with factors such as drug safety, level interchangeability, manufacturing site and active pharmaceutical ingredient quality, supply track record, and real-life outcomes. MCDA simple scoring can be applied to pharmaceutical pricing, reimbursement, formulary listing, and drug procurement. In November 2015, a workshop was held at the International Society for Pharmacoeconomics and Outcomes Research Annual Meeting in Milan to refine and prioritize criteria that can be used in MCDA simple scoring for OPPs, resulting in an example MCDA process and 22 prioritized criteria that health care systems in emerging countries can easily adapt to their own decision-making processes.

Original languageEnglish
Pages (from-to)1-6
Number of pages6
JournalValue in Health Regional Issues
Volume13
DOIs
Publication statusPublished - Sep 1 2017

Fingerprint

Decision Support Techniques
Pharmaceutical Preparations
Biomedical Technology Assessment
Multi-criteria decision analysis
Methodology
Evidence-based
Emerging markets
Patents
Pharmaceuticals
Scoring
Delivery of Health Care
Safety
Formularies
Costs and Cost Analysis
Cost Savings
Excipients
Health
Catalytic Domain
Decision Making
Emerging countries

Keywords

  • emerging markets
  • generic pharmaceuticals
  • health technology assessment
  • HTA
  • MCDA
  • MCDA simple scoring
  • multicriteria decision analysis
  • off-patent pharmaceuticals

ASJC Scopus subject areas

  • Economics, Econometrics and Finance (miscellaneous)
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
  • Health Policy

Cite this

Considering Multicriteria Decision Analysis (MCDA) Simple Scoring as an Evidence-Based HTA Methodology for Evaluating Off-Patent Pharmaceuticals (OPPs) in Emerging Markets. / Brixner, Diana; Maniadakis, Nikos; Kaló, Z.; Hu, Shanlian; Shen, Jie; Wijaya, Kalman.

In: Value in Health Regional Issues, Vol. 13, 01.09.2017, p. 1-6.

Research output: Contribution to journalArticle

@article{241eed5ba08847a485205d4ba78b0311,
title = "Considering Multicriteria Decision Analysis (MCDA) Simple Scoring as an Evidence-Based HTA Methodology for Evaluating Off-Patent Pharmaceuticals (OPPs) in Emerging Markets",
abstract = "Off-patent pharmaceuticals (OPPs) represent more than 60{\%} of the pharmaceutical market in many emerging countries, where they are frequently evaluated primarily on cost rather than with health technology assessment. OPPs are assumed to be identical to the originators. Branded and unbranded generic versions can, however, vary from the originator in active pharmaceutical ingredients, dosage, consistency formulation, excipients, manufacturing processes, and distribution, for example. These variables can alter the efficacy and safety of the product, negatively impacting both the anticipated cost savings and the population's health. In addition, many health care systems lack the resources or expertise to evaluate such products, and current assessment methods can be complex and difficult to adapt to a health system's needs. Multicriteria decision analysis (MCDA) simple scoring is an evidence-based health technology assessment methodology for evaluating OPPs, especially in emerging countries in which resources are limited but decision makers still must balance affordability with factors such as drug safety, level interchangeability, manufacturing site and active pharmaceutical ingredient quality, supply track record, and real-life outcomes. MCDA simple scoring can be applied to pharmaceutical pricing, reimbursement, formulary listing, and drug procurement. In November 2015, a workshop was held at the International Society for Pharmacoeconomics and Outcomes Research Annual Meeting in Milan to refine and prioritize criteria that can be used in MCDA simple scoring for OPPs, resulting in an example MCDA process and 22 prioritized criteria that health care systems in emerging countries can easily adapt to their own decision-making processes.",
keywords = "emerging markets, generic pharmaceuticals, health technology assessment, HTA, MCDA, MCDA simple scoring, multicriteria decision analysis, off-patent pharmaceuticals",
author = "Diana Brixner and Nikos Maniadakis and Z. Kal{\'o} and Shanlian Hu and Jie Shen and Kalman Wijaya",
year = "2017",
month = "9",
day = "1",
doi = "10.1016/j.vhri.2017.02.001",
language = "English",
volume = "13",
pages = "1--6",
journal = "Value in Health Regional Issues",
issn = "2212-1099",
publisher = "Elsevier USA",

}

TY - JOUR

T1 - Considering Multicriteria Decision Analysis (MCDA) Simple Scoring as an Evidence-Based HTA Methodology for Evaluating Off-Patent Pharmaceuticals (OPPs) in Emerging Markets

AU - Brixner, Diana

AU - Maniadakis, Nikos

AU - Kaló, Z.

AU - Hu, Shanlian

AU - Shen, Jie

AU - Wijaya, Kalman

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Off-patent pharmaceuticals (OPPs) represent more than 60% of the pharmaceutical market in many emerging countries, where they are frequently evaluated primarily on cost rather than with health technology assessment. OPPs are assumed to be identical to the originators. Branded and unbranded generic versions can, however, vary from the originator in active pharmaceutical ingredients, dosage, consistency formulation, excipients, manufacturing processes, and distribution, for example. These variables can alter the efficacy and safety of the product, negatively impacting both the anticipated cost savings and the population's health. In addition, many health care systems lack the resources or expertise to evaluate such products, and current assessment methods can be complex and difficult to adapt to a health system's needs. Multicriteria decision analysis (MCDA) simple scoring is an evidence-based health technology assessment methodology for evaluating OPPs, especially in emerging countries in which resources are limited but decision makers still must balance affordability with factors such as drug safety, level interchangeability, manufacturing site and active pharmaceutical ingredient quality, supply track record, and real-life outcomes. MCDA simple scoring can be applied to pharmaceutical pricing, reimbursement, formulary listing, and drug procurement. In November 2015, a workshop was held at the International Society for Pharmacoeconomics and Outcomes Research Annual Meeting in Milan to refine and prioritize criteria that can be used in MCDA simple scoring for OPPs, resulting in an example MCDA process and 22 prioritized criteria that health care systems in emerging countries can easily adapt to their own decision-making processes.

AB - Off-patent pharmaceuticals (OPPs) represent more than 60% of the pharmaceutical market in many emerging countries, where they are frequently evaluated primarily on cost rather than with health technology assessment. OPPs are assumed to be identical to the originators. Branded and unbranded generic versions can, however, vary from the originator in active pharmaceutical ingredients, dosage, consistency formulation, excipients, manufacturing processes, and distribution, for example. These variables can alter the efficacy and safety of the product, negatively impacting both the anticipated cost savings and the population's health. In addition, many health care systems lack the resources or expertise to evaluate such products, and current assessment methods can be complex and difficult to adapt to a health system's needs. Multicriteria decision analysis (MCDA) simple scoring is an evidence-based health technology assessment methodology for evaluating OPPs, especially in emerging countries in which resources are limited but decision makers still must balance affordability with factors such as drug safety, level interchangeability, manufacturing site and active pharmaceutical ingredient quality, supply track record, and real-life outcomes. MCDA simple scoring can be applied to pharmaceutical pricing, reimbursement, formulary listing, and drug procurement. In November 2015, a workshop was held at the International Society for Pharmacoeconomics and Outcomes Research Annual Meeting in Milan to refine and prioritize criteria that can be used in MCDA simple scoring for OPPs, resulting in an example MCDA process and 22 prioritized criteria that health care systems in emerging countries can easily adapt to their own decision-making processes.

KW - emerging markets

KW - generic pharmaceuticals

KW - health technology assessment

KW - HTA

KW - MCDA

KW - MCDA simple scoring

KW - multicriteria decision analysis

KW - off-patent pharmaceuticals

UR - http://www.scopus.com/inward/record.url?scp=85019129597&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019129597&partnerID=8YFLogxK

U2 - 10.1016/j.vhri.2017.02.001

DO - 10.1016/j.vhri.2017.02.001

M3 - Article

C2 - 29073981

AN - SCOPUS:85019129597

VL - 13

SP - 1

EP - 6

JO - Value in Health Regional Issues

JF - Value in Health Regional Issues

SN - 2212-1099

ER -